A national situationer before NHMRC interim advice on puberty suppression
Australia is approaching an important point in the national debate about the clinical treatment of children and adolescents experiencing gender dysphoria.
In January 2025, the Australian Government asked the National Health and Medical Research Council (NHMRC) to develop new national clinical practice guidelines for the care of trans and gender diverse people under 18 with gender dysphoria. The existing Australian Standards of Care and Treatment Guidelines for Trans and Gender Diverse Children and Adolescents were not NHMRC-approved guidelines.
Federal Health Minister Mark Butler, quoting advice from NHMRC, described the field as contested and evolving.
The NHMRC process is now underway. Its current timetable provides for interim advice on puberty suppression to be released for public consultation in late 2026, followed by draft full guidelines in 2027 and final guidelines in 2028. The interim advice will therefore arrive into an Australian system that is already divided between jurisdictions.
The national question: what is the evidence and what should clinical practice look like?
The Commonwealth does not directly run the public paediatric gender services that are at the centre of this debate. Public health services are administered by the states and territories.
The Federal Government has instead asked NHMRC to develop a national evidence-based framework.
NHMRC says the new guidelines are being developed through a multidisciplinary committee, evidence review, stakeholder engagement, public consultation and declaration and management of interests. The process follows NHMRC’s formal guideline standards and the international GRADE approach to assessing evidence and recommendations.
Puberty suppression has been prioritised. The current NHMRC timetable provides for public consultation on interim advice in November–December 2026. The full guidelines are expected to address puberty suppression as well as gender-affirming hormone treatment, with final publication anticipated in 2028.
The NHMRC process may produce national clinical guidance, but it does not itself determine the health policy of every state or territory. Nor does it automatically determine what treatment will be available through each public health system. Federal Health Minister Mark Butler stated that the provision of public gender services to young people in Australia is exclusively led by the states and territories, which are responsible for the relevant services and employ the relevant clinicians.
Australia therefore enters the NHMRC process with different jurisdictions already making different decisions.
Queensland: the major turning point
Queensland became the most significant Australian test case when it paused the initiation of puberty suppression and gender-affirming hormone treatment for new patients under 18 in its public paediatric gender services in January 2025.
The Government commissioned an independent review led by Professor Ruth Vine. The review examined the evidence and ethical considerations surrounding Stage 1 puberty suppression and Stage 2 gender-affirming hormones and provided policy advice to the Queensland Government.
The Vine Review was released on 19 December 2025. The review considered the available evidence and set out policy options for Queensland. The evidence base was characterised as limited, with particular uncertainty concerning longer-term benefits and risks. The report also identified risks associated with restricting treatment, including potential inequity and the possibility of treatment shifting to private or interstate services.
The Queensland Cabinet nevertheless chose to continue the public-system pause.
The Government stated that the pause would remain until the results of the UK PATHWAYS trial, expected in 2031, were available. Existing Queensland public patients who had commenced treatment before the original January 2025 restriction were permitted to continue treatment.
The Queensland legal dispute
The Queensland policy has also generated significant litigation. The original January 2025 Queensland Health directive was challenged in the Supreme Court.
In AB v Chief Executive of Queensland Health [2025] QSC 277, the Supreme Court set aside that particular directive. The case concerned the legality of the decision-making process, including the exercise of the statutory power and consultation requirements. The Court did not determine whether puberty blockers or gender-affirming hormones were clinically appropriate.
On the same day, 28 October 2025, the Health Minister issued a new Ministerial Direction under section 44 of the Hospital and Health Boards Act 2011 (Qld). That direction reinstated the public-system restriction.
The direction was subsequently amended in January 2026 and remains in force.
The policy has continued to be contested. In June 2026, the Queensland Civil and Administrative Tribunal dealt with SP by PY v State of Queensland [2026] QCAT 245, concerning a complaint relating to the restriction of Stage 1 and Stage 2 treatment.
As at September 2026, therefore, the Queensland policy remains in place while also being the subject of continuing legal and policy debate.
The Northern Territory follows Queensland
In December 2025, the Northern Territory Government announced that puberty blockers and gender-affirming hormone treatment would no longer be publicly funded for children.
The policy followed Queensland’s decision.
The NT Government said the change would affect a small number of young people who had been accessing treatment through the NT public health system. The public system’s focus was redirected towards adolescent mental health services.
The significance of the NT decision is primarily that it created a second Australian jurisdiction in which access to these treatments was withdrawn from the public system.
It should not, however, be described as an absolute prohibition. Public-system access and private prescribing are different questions.
By September 2026, Queensland and the Northern Territory had therefore adopted public-system restrictions while other Australian jurisdictions had not adopted the same policy.
A divided Australian system
Australia consequently does not have one uniform system for the treatment of minors experiencing gender dysphoria.
Queensland restricts initiation of Stage 1 and Stage 2 treatment for new patients in its public system. The Northern Territory has also withdrawn public access.
Other jurisdictions continue to operate specialist services.
Western Australia’s Perth Children’s Hospital Gender Diversity Service, for example, continues to provide assessment and treatment to young people. WA Parliament was told in March 2026 that the service was treating 215 patients, with patients from 11 years of age, while surgical interventions for gender affirmation were not offered by the Child and Adolescent Health Service at any age.
The result is a geographically divided system in which the treatment available to an adolescent can depend partly on the state or territory in which that young person lives and whether care is sought through a public or private pathway.
This is one reason the forthcoming national NHMRC guidance matters. It may not create identical services across Australia, but it has the potential to establish a common evidence-based reference point for clinical practice.
The national data and outcomes problem
One of the clearest problems in the Australian debate is the absence of a comprehensive national dataset. There is no national registry recording all Australian children receiving puberty suppression for gender dysphoria, their age and sex at commencement, subsequent treatments, treatment cessation or longer-term outcomes. Information is held by individual services and jurisdictions, and public reporting is inconsistent.
The medicines used (gonadotrophin-releasing hormone analogues) are TGA-approved for other indications, such as precocious puberty. Their use for gender dysphoria is off-label. Documents obtained under FOI, record the TGA’s position that it has not assessed efficacy and safety for this indication, and that without efficacy and usage data it cannot assess the risk–benefit profile or calculate adverse-event rates for that use.
This matters because puberty suppression is not necessarily the end of the clinical pathway. For some young people it is followed by gender-affirming hormones, which can produce physical changes that are not fully reversible.
Australia therefore lacks a consistent picture of who enters treatment, what follows, what is monitored (including bone health and fertility), how many stop, and what happens later.
NHMRC can assess the evidence that exists. It cannot invent Australian longitudinal data that were never collected. Better national data collection and long-term follow-up belong in any future clinical governance, whatever the interim advice concludes.
Surgery is a separate and more limited controversy
Claims about surgery on minors are often mixed together with the separate debate about puberty suppression and hormones.
The Australian position is more complicated.
The Australian Human Rights Commission’s current explainer states that most gender-affirming surgeries are not available to people under 18 in the public health system and identifies mastectomies for trans-identified females in very extreme circumstances as an exception.
At the same time, Australian legal and clinical material has recognised the possibility of mastectomy through private pathways in particular circumstances.
Western Australia illustrates why the distinction between public hospital treatment and private referral matters.
In March 2026, the WA Parliament was told that Perth Children’s Hospital’s Gender Diversity Service was treating patients from age 11, but that the Child and Adolescent Health Service did not itself provide gender-affirming surgery at any age. A model-of-care document associated with the service, later tabled in Parliament, describes providing details of private surgeons for “top surgery” while placing responsibility for the choice on the young person and family.
The relevant question is therefore not whether the public children’s hospital performs the operation. It is whether, and under what circumstances, young people can be assessed or referred through private pathways for mastectomy, and what safeguards apply.
That is a legitimate question for public scrutiny, particularly where national data on the number and characteristics of procedures involving minors are limited.
Parents, consent and children outside the clinic
Clinical treatment is only one part of the broader question.
Children experiencing gender distress also encounter schools, families and other institutions. Questions can arise about social transition, names and pronouns, school records, access to facilities, parental notification and the role of parents in decision-making.
These issues should not be confused with the NHMRC clinical review. NHMRC’s guidelines concern clinical care; they do not establish a national school policy.
Australian law also recognises that children and adolescents can have different levels of decision-making capacity depending on their circumstances. Parental involvement therefore cannot simply be reduced to either “parents decide everything” or “children decide everything”.
For WSA, the central issue is that decisions involving children should be transparent, proportionate and consistent with the child’s welfare, while parents should not be deliberately excluded from significant decisions about their children except where there is a proper child-protection or legal basis for doing so.
These questions warrant their own policy examination. They should not, however, be allowed to obscure the immediate national clinical question now before NHMRC.
Conclusion
Gender medicine for children is now a contested field in Australia. That is not a slogan. It is the description used when the Commonwealth sent the issue to NHMRC.
Queensland and the Northern Territory have paused new publicly funded puberty suppression and gender-affirming hormones for minors. Other jurisdictions have not. The Vine Review found the evidence limited; Queensland Cabinet, not the reviewers, chose the pause. The courts have tested how Queensland made that decision. They have not settled whether these treatments are safe or effective.
What remains unanswered is basic. How many children are treated, at what age and sex, what follows, what is monitored, who stops, and what happens later. The TGA has said it cannot assess the risk–benefit profile of this off-label use without efficacy and usage data. A guideline process cannot invent those figures.
Women Speak Australia starts from the child. Children are male or female. Distress is real and deserves care. Distress does not change sex. Care should be evidence-based, cautious where evidence is weak, and open to parents except where a proper child-protection threshold is met. Powerful interventions in a developing body require transparent data and long-term follow-up, not an assumption that the pathway is settled.
The next public document is NHMRC’s interim advice on puberty suppression.
Until then, governments should not wait for 2028 to collect the numbers, keep parents in the room, or treat sex as a fact about the child. The review can still be useful. It is not a reason for silence.